Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATE: Etigilimab + Nivolumab in Advanced Solid Tumors
NCT04761198Phase 2Completed
- Sponsor
- Mereo BioPharma
- Start
- Mar 2021
- Primary completion
- Oct 2023
- Modality
- IgG Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of etigilimab in endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC), cervical carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Mereo BioPharma. Started Mar 2021; status: completed.
02
Drugs
etigilimab
03
Conditions
endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)cervical carcinomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04761198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761198.